{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "COVID-19 vaccines",
      "CanSino",
      "Delta",
      "Latin America",
      "Mexico",
      "Mu",
      "SARS-CoV-2",
      "surveillance",
      "variant of concern"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35062359",
  "DateCompleted": {
    "Year": "2022",
    "Month": "02",
    "Day": "04"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "07",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "01",
        "Day": "14"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "154",
      "10.3390/v14010154"
    ],
    "Journal": {
      "ISSN": "1999-4915",
      "JournalIssue": {
        "Volume": "14",
        "Issue": "1",
        "PubDate": {
          "Year": "2022",
          "Month": "Jan",
          "Day": "14"
        }
      },
      "Title": "Viruses",
      "ISOAbbreviation": "Viruses"
    },
    "ArticleTitle": "Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico.",
    "Abstract": {
      "AbstractText": [
        "SARS-CoV-2 variants of concern (VOCs) or of interest (VOIs) causing vaccine breakthrough infections pose an increased risk to worldwide public health. An observational case-control study was performed of SARS-CoV-2 vaccine breakthrough infections in hospitalized or ambulatory patients in Monterrey, Mexico, from April through August 2021. Vaccination breakthrough was defined as a SARS-CoV-2 infection that occurred any time after 7 days of inoculation with partial (e.g., first dose of two-dose vaccines) or complete immunization (e.g., second dose of two-dose vaccines or single-dose vaccine, accordingly). Case group patients (<i>n</i> = 53) had partial or complete vaccination schemes with CanSino (45%), Sinovac (19%), Pfizer/BioNTech (15%), and AstraZeneca/Oxford (15%). CanSino was administered most frequently in ambulatory patients (<i>p</i> < 0.01). The control group (<i>n</i> = 19) received no COVID-19 vaccines. Among SARS-CoV-2 variants detected by whole-genome sequencing, VOC Delta B.1.617.2 predominated in vaccinated ambulatory patients (<i>p</i> < 0.01) and AY.4 in hospitalized patients (<i>p</i> = 0.04); VOI Mu B.1.621 was detected in four (7.55%) vaccinated patients. SARS-CoV-2 breakthrough infections in our hospital occurred mostly in patients vaccinated with CanSino due to the higher prevalence of CanSino vaccine administration in our population. These patients developed mild COVID-19 symptoms not requiring hospitalization. The significance of this study lies on the detection of SARS-CoV-2 variants compromising the efficacy of local immunization therapies in Monterrey, Mexico."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0002-3495-0528"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Investigation and Innovation in Medical Virology, Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey 64460, Mexico."
          }
        ],
        "LastName": "Gal\u00e1n-Huerta",
        "ForeName": "Kame A",
        "Initials": "KA"
      },
      {
        "Identifier": [
          "0000-0003-1259-7425"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectious Diseases, School of Medicine, University Hospital \"Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\", Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey 64460, Mexico."
          }
        ],
        "LastName": "Flores-Trevi\u00f1o",
        "ForeName": "Samantha",
        "Initials": "S"
      },
      {
        "Identifier": [
          "0000-0002-6755-0854"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectious Diseases, School of Medicine, University Hospital \"Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\", Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey 64460, Mexico."
          }
        ],
        "LastName": "Salas-Trevi\u00f1o",
        "ForeName": "Daniel",
        "Initials": "D"
      },
      {
        "Identifier": [
          "0000-0003-4602-3817"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectious Diseases, School of Medicine, University Hospital \"Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\", Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey 64460, Mexico."
          }
        ],
        "LastName": "Bocanegra-Ibarias",
        "ForeName": "Paola",
        "Initials": "P"
      },
      {
        "Identifier": [
          "0000-0003-2311-2534"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Investigation and Innovation in Medical Virology, Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey 64460, Mexico."
          }
        ],
        "LastName": "Rivas-Estilla",
        "ForeName": "Ana M",
        "Initials": "AM"
      },
      {
        "Identifier": [
          "0000-0002-6642-2770"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectious Diseases, School of Medicine, University Hospital \"Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\", Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey 64460, Mexico."
          }
        ],
        "LastName": "P\u00e9rez-Alba",
        "ForeName": "Eduardo",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Investigation and Innovation in Medical Virology, Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey 64460, Mexico."
          }
        ],
        "LastName": "Lozano-Sep\u00falveda",
        "ForeName": "Sonia A",
        "Initials": "SA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Investigation and Innovation in Medical Virology, Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey 64460, Mexico."
          }
        ],
        "LastName": "Arellanos-Soto",
        "ForeName": "Daniel",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectious Diseases, School of Medicine, University Hospital \"Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\", Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey 64460, Mexico."
          }
        ],
        "LastName": "Camacho-Ortiz",
        "ForeName": "Adri\u00e1n",
        "Initials": "A"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Observational Study",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Viruses",
    "NlmUniqueID": "101509722",
    "ISSNLinking": "1999-4915"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    }
  ],
  "SupplMeshList": [
    "COVID-19 breakthrough infections",
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [
        "epidemiology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Case-Control Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Hospitalization"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Hospitals, University"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Mexico"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Phylogeny"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prevalence"
    },
    {
      "QualifierName": [
        "classification",
        "genetics",
        "isolation & purification"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vaccination"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vaccine Efficacy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Whole Genome Sequencing"
    }
  ],
  "CoiStatement": "The authors declare no conflict of interest."
}